![](/-/media/editorial/scrip/2024/06/sc2406_amgen1000oaks_2179492463_1200.jpg?rev=78db9565514a4c3e99706d9fd479f6de&w=350&hash=BB10753310161452BBA3A8FD182BFC32)
Amgen’s Ian Thompson On Payer Shifts, Obesity Opportunity And The Future Of Blockbusters
Scrip spoke with Amgen’s senior VP of US business operations about the impact of drug pricing and reimbursement pressures coming from government policy changes and commercial payers.
![](/-/media/editorial/scrip/2024/06/sc062024_1909870405_-blue-shoot.jpg?rev=69980cee87f64612ba92093dfa34f2cc&w=350&hash=7D1B55C6E996AB4B4342215675AD1516)
Ashibio Takes Shelved Gilead Drug In New Direction
On the back of a “truly one in a million” case, Ashibio has revived research into Gilead's discontinued asset andecaliximab after it showed promise in the ultra-rare musculoskeletal condition FOP.
![](/-/media/editorial/scrip/2024/06/sc2406_parexelexecutives_1200.jpg?rev=90c4f7ad5cb84d0eb3b39a697d560d5b&w=350&hash=9D5E08446735DE96B14F1C91D707102E)
Parexel Execs On Obesity Drug Hurdles, Parexel GPT, India RWD Opportunity
Parexel’s chief strategy officer Kushal Gohil, Clinical EVP Stephen Pyke and India head Sanjay Vyas share thoughts on possible hurdles to, and the cascading impact of obesity treatments, GenAI progress and the opportunities and challenges of real-world data in India, in the second of this two-part interview with Scrip.
![](/-/media/editorial/headshots/corporate/e/ettenberg_seth_1200.jpg?rev=1b55a2f6c02e4d9dad2c6a8e45db818c&w=350&hash=9F48EBE6FC636CE0DB235945C5C0932D)
Bayer's Bets In Parkinson's Start To Bear Fruit
The German major is kicking off Phase II trials for a cell therapy and a gene therapy that could be gamechangers for the progressive neurodegenerative disorder that affects more than 10 million people worldwide.
![](/-/media/editorial/scrip/2024/06/joerg-ahlgrimm-ceo-sk-pharmteco-at-bio-usa.jpg?rev=26aa1c8639f743bfb6e0506bd5fbe6a7&w=350&hash=0CF7CE7982402F946BB75C6832755766)
SK pharmteco Focusing On BAU Amid BIO 'Buzz', BIOSECURE
SK pharmteco CEO Joerg Ahlgrimm talks to Scrip about the "excitement" at BIO, potential CDMO shifts amid the US BIOSECURE Act, and the Korean CDMO's focus on business as usual as it seeks to diversify and grow.
![](/-/media/editorial/scrip/2024/06/sc2406_parexelexecutives_1200.jpg?rev=90c4f7ad5cb84d0eb3b39a697d560d5b&w=350&hash=9D5E08446735DE96B14F1C91D707102E)
Parexel On Reimbursement Support, Federated Data Sharing, Diversity Through Communities
Parexel’s chief strategy officer, clinical EVP and India head share thoughts on a winner’s mindset for artificial intelligence, benefits of a “federated approach” to clinical data sharing, support for reimbursement and a cascading impact of obesity treatments, in a two-part interview with Scrip.
![](/-/media/editorial/scrip/2024/06/sun-north-america-ceo-abhay-gandhi-1200x675.jpg?rev=7fdbe8525ff6405d898e6ce4605e0f59&w=350&hash=CE5257454E966DDF5EA2D7615650D887)
Sun’s Gandhi On US Specialty Journey Sans ‘Baggage’, Deuruxolitinib
Sun’s CEO (North America) Abhay Gandhi tells Scrip how not many gave the firm a chance in the US with Ilumya, now with global sales of over half a billion dollars, and outlines prospects of deuruxolitinib for alopecia areata. India’s top-ranked drug maker also has an eye on China R&D assets.
![](/-/media/editorial/scrip/00_regular-column-images/finance_watch_private_company_1200_675.jpg?rev=08e535103fc64137a8ebefc93306626d&w=350&hash=9AB8CAA21A02F4913A32E237402983A4)
Finance Watch: Lilly’s Gateway Labs, Deerfield’s Cure Offer Biotechs Space To Grow
Private Company Edition: Scrip spoke with the leaders of Gateway Labs and Cure at the BIO International Convention about their mini ecosystems. Also, radiopharmaceutical firm ITM raised €188m ($201.9m), Santa Ana Bio emerged with $168m and Alzheon’s series E totaled $100m.
![](/-/media/editorial/buildings/corporate/b/bayer-cross.jpg?rev=79fba18434dc44db89b9f4c7b1b25e77&w=350&hash=50DADA254D204BFDF7AE166B431787CC)
BIO: Bayer Operational Model Benefits From Its Arm’s Length Biotechs
There is a lot of structural change going on at the German major but it is learning from the way its wholly owned subsidiaries such as AskBio and BlueRock are run.
![](/-/media/editorial/headshots/corporate/s/schafer_josh_1200.png?rev=4ba70e658a4347faaa847f5e7ec9129b&w=350&hash=51A29024F0369B8825C8B018DC6A348C)
BIO: Upbeat Zevra Advances Promising Rare Disease Portfolio
With the urea cycle disorder treatment Olpruva launched and the NPC therapy arimoclomol closing in on US approval, Zevra is one to watch in the rare disease space.
![](/-/media/editorial/scrip/2024/06/sc2406_bigbluedollarsign_2229781123_1200.jpg?rev=012c53f3d71044f8bef95de1915b8ce3&w=350&hash=755900E60A65889DD4466BDD175D2042)
Foresite Closes $900m Fund VI As Financial Condition Rebound Begins
Foresite Capital already has invested in multiple high-profile therapeutics firms with its sixth fund, including private Xaira, newly public CG Oncology, and Alumis, which is on the verge of an IPO.
![](/-/media/editorial/scrip/2024/05/sc2405_two_planes_1337793689_1200.jpg?rev=4c814884ebb04cbfa7ff32172d798075&w=350&hash=D1BD352A5E2FA83F4BD028D7D25528F3)
Astellas’s US Commercial Head Petroutsas On New Launches
The Japanese pharma’s new US commercial head Michael Petroutsas talked to Scrip about the launches of Veozah and Izervay.
![](/-/media/editorial/headshots/corporate/l/lopes-fernandes_philippe.jpg?rev=e5a75dc318aa4e9695d27a71f381a2f6&w=350&hash=08F589F42348A035B39F846FA4927E5F)
Ipsen Dealmaking Heats Up With Marengo Cold Tumor Collaboration
The France-based mid-sized drugmaker has solidified its pipeline through several external pacts in the past few years and its dealmaking is showing no signs of slowing down.
![](/-/media/editorial/scrip/00_regular-column-images/sc2406_the_scrip_awards_podcast_1200.jpg?rev=db1ed9c73a68450c87b2726c6d6bcc7b&w=350&hash=EBAB1215BC4D2C93E34E154E29891568)
The Scrip Awards Podcast, Episode 1: Genmab: The Ongoing Evolution Of Europe’s Antibody Powerhouse
A new podcast series marking 20 years of the Scrip Awards and their recognition of biopharma sector innovation.
![](/-/media/editorial/scrip/00_regular-column-images/sc2105_generic_podcast_image_1200.jpg?rev=a915298bdfd641a99ffa517f309bffed&w=350&hash=FB40DD2CD79E2524004CF689687002E6)
Amid Talk Of KKR Stake Sale, JB CEO Stresses Business As Usual
In an interview with JB CEO Nikhil Chopra, Scrip discusses talk of a stake sale by private equity fund KKR, gains from acquisitions including select Novartis brands, plans to ascend to the top five in cardiology and a ramp up of the CDMO business, which has clients including J&J.
![](/-/media/editorial/scrip/2024/05/sc2405-syntekabio_heakyoung-cho.jpg?rev=437ae6363edb475d9da1d38521bcfb52&w=350&hash=D0DE1D07DEA497537290C5F5A7D7515C)
Korea Looks To Close Gap In AI Drug Development Capabilities
Syntekabio CSO HeaKyoung Cho talks to Scrip how the AI-driven drug development situation in Korea compares with global trends and what the domestic industry needs to do to survive rising competition at home and abroad.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.